nach oben

CNS Drugs

Erschienen in:

01.09.2009 | Leading Article

Tumour Necrosis Factor Modulation for Treatment of Alzheimer’s Disease

Rationale and Current Evidence

verfasst von: Edward Tobinick

Erschienen in: CNS Drugs | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Abstract

Tumour necrosis factor (TNF), a key regulator of varied physiological mechanisms in multiple organ systems, is an immune signalling molecule produced by glia, neurons, macrophages and other immune cells. In the brain, among other functions, TNF serves as a gliotransmitter, secreted by glial cells that envelope and surround synapses, which regulates synaptic communication between neurons. The role of TNF as a gliotransmitter may help explain the profound synaptic effects of TNF that have been demonstrated in the hippocampus, in the spinal cord and in a variety of experimental models. Excess TNF is present in the CSF of individuals with Alzheimer’s disease (AD), and has been implicated as a mediator of the synaptic dysfunction that is hypothesized to play a central role in the pathogenesis of AD. TNF may also play a role in endothelial and microvascular dysfunction in AD, and in amyloidogenesis and amyloid-induced memory dysfunction in AD. Genetic and epidemiological evidence has implicated increased TNF production as a risk factor for AD.

Perispinal administration of etanercept, a potent anti-TNF fusion protein, produced sustained clinical improvement in a 6-month, open-label pilot study in patients with AD ranging from mild to severe. Subsequent case studies have documented rapid clinical improvement following perispinal etanercept in both AD and primary progressive aphasia, providing evidence of rapidly reversible, TNF-dependent, pathophysiological mechanisms in AD and related disorders. Perispinal etanercept for AD merits further study in randomized clinical trials.

TNF as used herein is synonymous with TNFa. The nomenclature for TNF has changed over time. Upon recommendation of the 7th International TNF Congress (17–21 May 1998; Hyannis, MA, USA),[3] the names for TNFα and TNFβ were changed to TNF and lymphotoxin-a (LTα), respectively.

Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007; 18(3–4): 335–43PubMedCrossRef

Perry RT, Collins JS, Wiener H, et al. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging 2001; 22(6): 873–83PubMedCrossRef

Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008; 117(2): 244–79PubMedCrossRef

Vitkovic L, Bockaert J, Jacque C. “Inflammatory” cytokines: neuromodulators in normal brain? J Neurochem 2000; 74(2): 457–71PubMedCrossRef

Halassa MM, Fellin T, Haydon PG. The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 2007; 13(2): 54–63PubMedCrossRef

Chung IY, Benveniste EN. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 1990; 144(8): 2999–3007

Sawada M, Kondo N, Suzumura A, et al. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989; 491(2): 394–7PubMedCrossRef

Kinouchi K, Brown G, Pasternak G, et al. Identification and characterization of receptors for tumor necrosis factor-alpha in the brain. Biochem Biophys Res Commun 1991; 181(3): 1532–8PubMedCrossRef

Pickering M, Cumiskey D, O’Connor JJ. Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 2005; 90(5): 663–70PubMedCrossRef

10.

Bains JS, Oliet SH. Glia: they make your memories stick! Trends Neurosci 2007; 30(8): 417–24PubMedCrossRef

11.

Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 2005; 6(8): 626–40PubMedCrossRef

12.

The 2007 Progress report on brain research. The Dana Alliance for Brain Research. New York: The Dana Foundation, 2007

13.

Goddard CA, Butts DA, Shatz CJ. Regulation of CNS synapses by neuronal MHC class I. Proc Natl Acad Sci U S A 2007; 104(16): 6828–33PubMedCrossRef

14.

Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975; 72(9): 3666–70PubMedCrossRef

15.

Tobinick EL. Targeted etanercept for treatment-refractory pain due to bone metastasis: two case reports. Clin Ther 2003; 25(8): 2279–88PubMedCrossRef

16.

Feldmann M, Maini RN. Lasker Clinical Medical Research Award: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9(10): 1245–50PubMedCrossRef

17.

Medeiros R, Prediger RD, Passos GF, et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer’s disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J Neurosci 2007; 27(20): 5394–404PubMedCrossRef

18.

Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000; 35(2): 151–9PubMedCrossRef

19.

Rowan MJ, Klyubin I, Wang Q, et al. Synaptic memory mechanisms: Alzheimer’s disease amyloid beta-peptide-induced dysfunction. Biochem Soc Trans 2007; 35 (Pt 5): 1219–23PubMedCrossRef

20.

Tancredi V, D’Arcangelo G, Grassi F, et al. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci Lett 1992; 146(2): 176–8PubMedCrossRef

21.

Beattie EC, Stellwagen D, Morishita W, et al. Control of synaptic strength by glial TNFalpha. Science 2002; 295(5563): 2282–5PubMedCrossRef

22.

Bennett MR. The concept of long term potentiation of transmission at synapses. Prog Neurobiol 2000; 60(2): 109–37PubMedCrossRef

23.

Stellwagen D, Beattie EC, Seo JY, et al. Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. J Neurosci 2005; 25(12): 3219–28PubMedCrossRef

24.

Youn DH, Wang H, Jeong SJ. Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J Neurosci Res 2008; 86: 2867–75PubMedCrossRef

25.

Jin X, Gereau 4th RW. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci 2006; 26(1): 246–55PubMedCrossRef

26.

Yang T, Knowles JK, Lu Q, et al. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One 2008; 3(11): e3604PubMedCrossRef

27.

Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 2004; 44(1): 181–93PubMedCrossRef

28.

Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 2007; 53(3): 337–51PubMedCrossRef

29.

Ranaivo HR, Craft JM, Hu W, et al. Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 2006; 26(2): 662–70CrossRef

30.

LaFerla FM, Oddo S. Alzheimer’s disease: Abeta, tau and synaptic dysfunction. Trends Mol Med 2005; 11(4): 170–6PubMedCrossRef

31.

Bell KF, Claudio Cuello A. Altered synaptic function in Alzheimer’s disease. Eur J Pharmacol 2006; 545(1): 11–21PubMedCrossRef

32.

Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 2002; 298(5594): 789–91PubMedCrossRef

33.

Hu W, Ranaivo HR, Roy SM, et al. Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits. Bioorg Med Chem Lett 2007; 17(2): 414–8PubMedCrossRef

34.

Small DH. Mechanisms of synaptic homeostasis in Alzheimer’s disease. Curr Alzheimer Res 2004; 1(1): 27–32PubMedCrossRef

35.

Wang Q, Wu J, Rowan MJ, et al. Beta-amyloid inhibition of long-term potentiation is mediated via tumor necrosis factor. Eur J Neurosci 2005; 22(11): 2827–32PubMedCrossRef

36.

Alkam T, Nitta A, Mizoguchi H, et al. Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice. Behav Brain Res 2008; 189(1): 100–6PubMedCrossRef

37.

Turrigiano GG, Leslie KR, Desai NS, et al. Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature 1998; 391(6670): 892–6PubMedCrossRef

38.

Small DH. Network dysfunction in Alzheimer’s disease: does synaptic scaling drive disease progression? Trends Mol Med 2008; 14(3): 103–8PubMedCrossRef

39.

Chang EH, Savage MJ, Flood DG, et al. AMPA receptor downscaling at the onset of Alzheimer’s disease pathology in double knockin mice. Proc Natl Acad Sci U S A 2006; 103(9): 3410–5PubMedCrossRef

40.

Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature 2006; 440(7087): 1054–9PubMedCrossRef

41.

Savin C, Triesch J, Meyer-Hermann M. Epileptogenesis due to glia-mediated synaptic scaling. J R Soc Interface. Epub 2008 Nov 4

42.

Tobinick E, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 2008; 8: 27PubMedCrossRef

43.

Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 2008; 5: 2PubMedCrossRef

44.

Gosselin D, Rivest S. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav Immun 2007; 21(3): 281–9

45.

Tarkowski E, Blennow K, Wallin A, et al. Intracerebral production of tumor necrosis factor-alpha, a local neuro-protective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 1999; 19(4): 223–30PubMedCrossRef

46.

Tarkowski E, Andreasen N, Tarkowski A, et al. Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003; 74(9): 1200–5PubMedCrossRef

47.

Chiarini A, Dal Pra I, Whitfield JF, et al. The killing of neurons by beta-amyloid peptides, prions, and pro-inflammatory cytokines. Ital J Anat Embryol 2006; 111(4): 221–46PubMed

48.

De A, Krueger JM, Simasko SM. Glutamate induces the expression and release of tumor necrosis factor-alpha in cultured hypothalamic cells. Brain Res 2005; 1053(1–2): 54–61PubMedCrossRef

49.

Edwards MM, Robinson SR. TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer’s disease. J Neural Transm 2006; 113: 1709–13PubMedCrossRef

50.

Floden AM, Li S, Combs CK. Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 2005; 25(10): 2566–75PubMedCrossRef

51.

Meme W, Calvo CF, Froger N, et al. Proinflammatory cytokines released from microglia inhibit gap junctions in astrocytes: potentiation by beta-amyloid. FASEB J 2006; 20(3): 494–6PubMed

52.

Taylor DL, Jones F, Kubota ES, et al. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand. J Neurosci 2005; 25(11): 2952–64PubMedCrossRef

53.

Zou JY, Crews FT. TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005; 1034(1–2): 11–24PubMedCrossRef

54.

Blasko I, Marx F, Steiner E, et al. TNFalpha plus IFN-gamma induce the production of Alzheimer beta-amyloid peptides and decrease the secretion of APPs. FASEB J 1999; 13(1): 63–8PubMed

55.

Yamamoto M, Kiyota T, Horiba M, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007; 170(2): 680–92PubMedCrossRef

56.

Combs CK, Karlo JC, Kao SC, et al. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci 2001; 21(4): 1179–88PubMed

57.

Mbebi C, de Aguilar JL, See V, et al. Antibody-bound beta-amyloid precursor protein stimulates the production of tumor necrosis factor-alpha and monocyte chemoattractant protein-1 by cortical neurons. Neurobiol Dis 2005; 19(1–2): 129–41PubMedCrossRef

58.

Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86(19): 7611–5PubMedCrossRef

59.

He P, Zhong Z, Lindholm K, et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer’s mice. J Cell Biol 2007; 178(5): 829–41PubMedCrossRef

60.

Janelsins MC, Mastrangelo MA, Park KM, et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 2008; 173: 1768–82PubMedCrossRef

61.

Csiszar A, Labinskyy N, Smith K, et al. Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol 2007; 170(1): 388–98PubMedCrossRef

62.

Zonta M, Angulo MC, Gobbo S, et al. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 2003; 6(1): 43–50PubMedCrossRef

63.

Gordon GR, Mulligan SJ, MacVicar BA. Astrocyte control of the cerebrovasculature. Glia 2007; 55(12): 1214–21PubMedCrossRef

64.

Takano T, Tian GF, Peng W, et al. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci 2006; 9(2): 260–7PubMedCrossRef

65.

Takano T, Han X, Deane R, et al. Two-photon imaging of astrocytic Ca2+ signaling and the microvasculature in experimental mice models of Alzheimer’s disease. Ann N Y Acad Sci 2007; 1097: 40–50PubMedCrossRef

66.

van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after TNFalpha blockade. Ann Rheum Dis 2009; 68: 362–6PubMedCrossRef

67.

Tobinick E. Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med 2008; 10(6): 135PubMed

68.

Laws SM, Perneczky R, Wagenpfeil S, et al. TNF polymorphisms in Alzheimer disease and functional implications on CSF beta-amyloid levels. Hum Mutat 2005; 26(1): 29–35PubMedCrossRef

69.

Ramos EM, Lin MT, Larson EB, et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol 2006; 63(8): 1165–9PubMedCrossRef

70.

Alvarez V, Mata IF, Gonzalez P, et al. Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet 2002; 114(5): 574–7PubMedCrossRef

71.

Lio D, Annoni G, Licastro F, et al. Tumor necrosis factor-alpha-308A/G polymorphism is associated with age at onset of Alzheimer’s disease. Mech Ageing Dev 2006; 127(6): 567–71PubMedCrossRef

72.

Tan ZS, Beiser AS, Vasan RS, et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007; 68(19): 1902–8PubMedCrossRef

73.

Stoll G, Jander S. The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol 1999; 58(3): 233–47PubMedCrossRef

74.

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999; 53 (3): 457-65

75.

Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001; 57(10): 1885–8PubMedCrossRef

76.

Bensouda-Grimaldi L, Mulleman D, Valat JP, et al. Adalimumab-associated multiple sclerosis. J Rheumatol 2007; 34(1): 239–40; discussion 240PubMed

77.

Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008; 59(1–2): 91–3PubMedCrossRef

78.

van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA 2. Neurology 1996; 47(6): 1531–4PubMedCrossRef

79.

Bohac D, Burke W, Cotter R, et al. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and tolerability of TNFR: Fc (etanercept) in the treatment of dementia of the Alzheimer type [abstract no. 315]. Neurobiol Aging 2002; 23(1 Suppl. 1): S1–606

80.

Burke W. Pilot study of thalidomide for Alzheimer’s disease. Eighth International Conference on Alzheimer’s Disease and Related Disorders; 2002 Jul 21–25; Stockholm

81.

Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005; 2(1): 3–14PubMedCrossRef

82.

Banks WA, Moinuddin A, Morley JE. Regional transport of TNF-alpha across the blood-brain barrier in young ICR and young and aged SAMP8 mice. Neurobiol Aging 2001; 22(4): 671–6PubMedCrossRef

83.

Banks WA, Plotkin SR, Kastin AJ. Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 1995; 2(3): 161–5PubMedCrossRef

84.

Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. Med-GenMed 2006; 8(1): 53

85.

Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940; 112: 138–49PubMedCrossRef

86.

Groen RJ, du Toit DF, Phillips FM, et al. Anatomical and pathological considerations in percutaneous vertebroplasty and kyphoplasty: a reappraisal of the vertebral venous system. Spine 2004; 29(13): 1465–71PubMedCrossRef

87.

Clemens HJ. Die Venensysteme der menschlichen Wirbsèaule; Morphologie und funktionelle Bedeutung. Berlin: De Gruyter, 1961

88.

Arnautovic KI, al-Mefty O, Pait TG, et al. The suboccipital cavernous sinus. J Neurosurg 1997; 86(2): 252–62PubMedCrossRef

89.

Anderson R. Diodrast studies of the vertebral and cranial venous systems to show their probable role in cerebral metastases. J Neurosurg 1951; 8(4): 411–22PubMedCrossRef

90.

Batson OV. The vertebral vein system, Caldwell Lecture, 1956. Am J Roentgenol 1957; 78(2): 195–212

91.

Johanson CE, Duncan JA, Stopa EG, et al. Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharm Res 2005; 22(7): 1011–37PubMedCrossRef

92.

Tobinick E, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes 2009 Feb 27; 2: 28PubMedCrossRef

93.

McGeer PL, Tobinick E, Kornelsen R, et al. PET imaging reveals that etanercept crosses the blood-cerebrospinal fluid but not the blood-brain barrier: implications for Alzheimer disease. J Alzheimers Dis. Epub 2009 May 11

94.

Tobinick E. Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today 2009 Feb; 14(3–4): 168–77PubMedCrossRef

95.

Vallejo MC, Beaman ST, Ramanathan S. Blurred vision as the only symptom of a positive epidural test dose. Anesth Analg 2006; 102(3): 973–4PubMedCrossRef

96.

Groen RJ, Groenewegen HJ, van Alphen HA, et al. Morphology of the human internal vertebral venous plexus: a cadaver study after intravenous Araldite CY 221 injection. Anat Rec 1997; 249(2): 285–94PubMedCrossRef

97.

Netter F. A compilation of paintings on the normal and pathologic anatomy of the nervous system. In: Netter F, editor. The Ciba collection of medical illustrations. Vol. 1. New York: CIBA, 1953

98.

Tobinick EL, Britschgi-Davoodifar S. Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly 2003; 133 (11–12): 170–7

99.

Tobinick E, Davoodifar S. Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin 2004; 20(7): 1075–85PubMedCrossRef

100.

Tobinick E, Gross H, Weinberger A, et al. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed 2006; 8(2): 25PubMed

101.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994

102.

McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7): 939–44PubMedCrossRef

103.

Rosen WG, Terry RD, Fuld PA, et al. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980; 7(5): 486–8PubMedCrossRef

104.

Verhey FR, Houx P, Van Lang N, et al. Cross-national comparison and validation of the Alzheimer’s Disease Assessment Scale: results from the European Harmonization Project for Instruments in Dementia (EURO-HARPID). Int J Geriatr Psychiatry 2004; 19(1): 41–50PubMedCrossRef

105.

Panisset M, Roudier M, Saxton J, et al. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994; 51(1): 41–5

106.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for theclinician. JPsychiatr Res 1975; 12(3): 189–98CrossRef

107.

Doraiswamy PM, Kaiser L, Bieber F, et al. The Alzheimer’s Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer’s disease. Alzheimer Dis Assoc Disord 2001; 15(4): 174–83PubMedCrossRef

108.

Woods SP, Delis DC, Scott JC, et al. The California Verbal Learning Test-second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Arch Clin Neuropsychol 2006; 21(5): 413–20PubMedCrossRef

109.

Hilsabeck RC, Schrager DA, Gouvier WD. Cross-validation of the two- and three-subtest short forms of the Wechsler Memory Scale-Revised. Appl Neuropsychol 1999; 6(4): 247–51PubMedCrossRef

110.

Moses Jr JA. Test review: Comprehensive Trail Making Test (CTMT). Arch Clin Neuropsychol 2004; 19(5): 703–8PubMedCrossRef

111.

Smith SR, Servesco AM, Edwards JW, et al. Exploring the validity of the Comprehensive Trail Making Test. Clin Neuropsychol 2008; 22(3): 507–18PubMedCrossRef

112.

Zec RF, Burkett NR, Markwell SJ, et al. A cross-sectional study of the effects of age, education, and gender on the Boston Naming Test. Clin Neuropsychol 2007; 21(4): 587–616PubMedCrossRef

113.

Baldo JV, Shimamura AP. Letter and category fluency in patients with frontal lobe lesions. Neuropsychology 1998; 12(2): 259–67PubMedCrossRef

114.

Fisher NJ, Tierney MC, Rourke BP, et al. Verbal fluency patterns in two subgroups of patients with Alzheimer’s disease. Clin Neuropsychol 2004; 18(1): 122–31PubMedCrossRef

115.

Harrison JE, Buxton P, Husain M, et al. Short test of semantic and phonological fluency: normal performance, validity and test-retest reliability. Br J Clin Psychol 2000; 39 Pt 2: 181–91CrossRef

116.

Tobinick E. Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res 2007; 4(5): 550–2PubMedCrossRef

117.

Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695–9PubMedCrossRef

Titel: Tumour Necrosis Factor Modulation for Treatment of Alzheimer’s Disease
Rationale and Current Evidence
verfasst von: Edward Tobinick
Publikationsdatum: 01.09.2009
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 9/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11310810-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2009

Armodafinil

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Asenapine

The Effect of Migraine Prophylaxis on Migraine-Related Resource Use and Productivity

Aripiprazole